Clinical Trials Logo

Filter by:
NCT ID: NCT05631782 Completed - Hemodialysis Clinical Trials

Effects of Shenkang Decoction on Creatinine and Blood Urea Nitrogen in Chronic Renal Failure Hemodialysis Patients

Start date: November 10, 2020
Phase: Early Phase 1
Study type: Interventional

To explore the clinical effect of Shenkang Decoction in chronic renal failure (CRF) patients with hemodialysis (HD).

NCT ID: NCT05631717 Recruiting - Clinical trials for Systemic Lupus Erythematosus

The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN

Start date: October 1, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the efficacy and safety of human umbilical cord mesenchymal stem cells and low-dose IL-2 in the treatment of LN

NCT ID: NCT05631678 Completed - Clinical trials for Locally Advanced or Metastatic NSCLC

Drug-drug Interaction Study Beteewn ASK120067 and Rifampicin or Itraconazole

Start date: June 6, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the effects of oral administration rifampicin or itraconazole capsules on the pharmacokinetics of ASK120067 and its metabolite CCB4580030 in healthy subjects. To evaluate the safety of ASK120067 tablets or combination with rifampicin capsules or itraconazole capsules in healthy subjects.

NCT ID: NCT05631613 Recruiting - Clinical trials for Hepatocellular Carcinoma

Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma

Start date: December 28, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this observational study is to evaluate properties of lipiodol-idarubicin emulsion mixed with the best regimen obtained in vitro study, including stability, viscosity,visibility under X-ray and deposition, in order to maximize the efficacy of idarubicin-cTACE for HCC.

NCT ID: NCT05631561 Active, not recruiting - Clinical trials for Type 2 Diabetes Mellitus (T2DM)

Endovascular Denervation for the Treatment of Type 2 Diabetes Mellitus

Start date: December 27, 2022
Phase: N/A
Study type: Interventional

This is a prospective, multicenter, single group feasibility clinical trial to evaluate the safety and efficacy of Endovascular denervation for the treatment of type 2 diabetes mellitus (T2DM) using the Endovascular denervation system (Generator and Catheter).

NCT ID: NCT05631509 Recruiting - Genetic Disease Clinical Trials

Genetic Study of Obstructive Azoospermia

Start date: July 1, 2021
Phase:
Study type: Observational

In 1% of men with infertility, obstructive azoospermia (OA) may occur in congenital absence of the vas (CAVD) or idiopathic obstructive azoospermia . Many studies have shown that the pathogenic genes of OA are CFTR and ADGRG2 genes, and the inheritance mode is autosomal recessive. Although the conventional assisted reproductive technology(PESA/TESA) can help these patients have children, male patients who carry mutations of the disease-causing genes (CFTR and ADGRG2) will also pass on their mutations to the next generation, which will increase the risk of male offspring infertility. Therefore, genetic detection of CFTR and ADGRG2 genes is very necessary for CAVD patients before assisted reproduction. Genetic diagnosis plays a key role in preventing the disease to the offspring.

NCT ID: NCT05631470 Completed - Stroke, Ischemic Clinical Trials

Diagnostic Accuracy for Hemodynamically ICAS of MR-FFR Comparing With Pressure-wire-based FFR.

Start date: June 18, 2019
Phase:
Study type: Observational

The aim of this study was to determine the diagnostic accuracy of MR-FFR to detect functionally significant ICAS comparing with pressure-wire-based FFR.

NCT ID: NCT05631418 Withdrawn - Recruitment Clinical Trials

Chinese Regional Spinal Muscular Atrophy Patient Registration Study

Start date: November 2022
Phase:
Study type: Observational [Patient Registry]

The primary objectives of this study are to obtain clinically meaningful data on the survival, outcomes, prognosis and treatment effect of all the patients with spinal muscular atrophy (SMA) 5q types 1 to 3 (according to international classification), being followed in the Children's Hospital, Zhejiang University School of Medicine since October 2019. The registry will collect retrospectively and prospectively the longitudinal data of the long-term follow-up for children patients, under real life conditions of current medical practice, in order to document the clinical evolution of patients (survival, motor, respiratory, orthopedic and nutritional and so on), the conditions of use of the treatments, the mortality rates of treated and untreated patients, the tolerance of the treatments, adverse events.

NCT ID: NCT05631262 Recruiting - Clinical trials for Selected Subjects With Advanced Solid Tumors

SKB264 Monotherapy in Selected Subjects With Advanced Solid Tumors

Start date: November 30, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety and efficacy of SKB264 monotherapy in subjects with selected advanced solid tumors.The study is divided into two parts: the Part Ⅰ consists of 5 cohorts, and the Part Ⅱ for expansion. Eligible subjects will receive SKB264 monotherapy, until there is no longer clinical benefit, intolerable toxicity, discontinuation of study treatment required by the subject, or other protocol-specified treatment discontinuation criteria, whichever occurs first.

NCT ID: NCT05631145 Completed - Depression, Anxiety Clinical Trials

MT Combined With XKSA for Depressive Symptoms During COVID-19

Start date: May 3, 2020
Phase: N/A
Study type: Interventional

Social isolation related mental health problems have raised many concerns during the COVID-19 outbreaks. Mental health care for people in quarantined hotels is in urgent need, but concrete program is rarely reported. Morita therapy and acupressure have been identified as effective treatments for regulating mood and sleep. The study aimed to examine whether Morita therapy (MT) combined with Xingnao Kaiqiao self-administered acupressure (XKSA) could improve depressive, anxiety symptoms and sleep quality in isolated people with depressive symptoms.